期刊
BONE MARROW TRANSPLANTATION
卷 42, 期 3, 页码 175-180出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2008.133
关键词
hemophagocytic lymphohistiocytosis; unrelated donor transplant; conditioning regimen; mortality; bone marrow graft
资金
- CIBMTR [U24-CA76518]
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- National Heart, Lung and Blood Institute
- Office of Naval Research
- Health Resources and Services Administration (DHHS)
- AABB
- Aetna
- American International Group Inc.
- American Society for Blood and Marrow Transplantation
- Amgen Inc.
We report outcomes after unrelated donor hematopoietic cell transplantation (HCT) for 91 patients with hemophagocytic lymphohistiocytosis (HLH) transplanted in the US in 1989-2005. Fifty-one percent were <1 year at HCT and 29% had Lansky performance scores <90%. Most (80%) were conditioned with BU, CY, and etoposide (VP16) with or without anti-thymocyte globulin. Bone marrow was the predominant graft source. Neutrophil recovery was 91% at day-42. The probabilities of grades 2-4 acute GVHD at day-100 and chronic GVHD at 5 years were 41 and 23%, respectively. The overall mortality rate was higher in patients who did not receive BU/CY/VP16-conditioning regimen (RR 1.95, P = 0.035). The 5-year probability of overall survival was 53% in patients who received BU/CY/VP16 compared to 24% in those who received other regimens. In the subset of patients with known disease-specific characteristics, only one of five patients with active disease at HCT is alive. For those in clinical remission at HCT (n = 46), the 5-year probability of overall survival was 49%. Early mortality rates after HCT were high, 35% at day-100. These data demonstrate that a BU/CY/VP16-conditioning regimen provides cure in approximately 50% of patients and future studies should explore strategies to lower early mortality.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据